Projects
Combination of radiotherapy, PD-1 blockade and an immune-modulatory cocktail to combat cervical and uterine cancer Ghent University
Analysis of plasma, platelets and urine nucleic acids: the value of liquid biopsy to improve diagnosis, follow-up and monitoring of treatment response of lung cancer and pancreatic cancer patients. University of Antwerp
Overcoming resistance to anti-PD1 blockade in uterine leiomyosarcomas KU Leuven
Uterine leiomyosarcomas (uLMS) are rare tumors, characterized by an aggressive clinical behavior and high risk of hematologic spread. Currently, no highly effective therapeutic agents are available for these patients, which leads to a very poor prognosis and emphasizes the urgent need for new therapeutic options. The onset of immune checkpoint blockade (ICB) has transformed the therapeutic landscape in oncology, showing unprecedented ...
Understanding triple negative breast cancer dependence on serine biosynthesis: new insights for targeted therapy. KU Leuven
Breast cancer is the second leading causes of cancer death among women. This issue is of particular relevance for Belgium, which has the highest incidence rate for breast cancer in Europe. Today we know that breast cancer is no single disease. Conversely, multiple subtypes exist, with different molecular basis, clinical outcomes and response to treatment. The challenge we face is therefore to understand the characteristics of each breast ...
Unraveling the regulation of serine biosynthesis in breast cancer cells. KU Leuven
Breast cancer is the most frequent type of tumor among women worldwide, accounting for 24.2% of all the tumor cases. Due to these tremendous incidences, breast cancer is also the type of tumor causing the highest number of deaths, indeed around 600.000 women die every year because of this disease. By taking a closer look at the prognosis of patients diagnosed with breast cancer, it appears evident that the progression of the disease towards a ...
Unraveling the resistance mechanisms to PI3K/mTOR inhibition and PD-1 blockade in uterine leiomyosarcoma KU Leuven
Uterine leiomyosarcomas (uLMS) are rare and aggressive cancers
with only limited treatment options. Five-year overall survival ranges
between 16% and 57%, depending on the stage of the disease.
uLMS show substantial inter- and intra-tumor heterogeneity making
them difficult to treat. Due to this heterogeneity, not all patients
respond equally to the same treatments, underscoring the urgent
need for new ...